BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34153177)

  • 1. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan.
    Huang YS; Wu CY; Chang TT; Peng CY; Lo GH; Hsu CW; Hu CT; Huang YH
    Liver Int; 2021 Nov; 41(11):2671-2680. PubMed ID: 34153177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
    Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
    Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results.
    Huang PW; Chiou MH; Chien MY; Chen WW; Chu CY
    J Formos Med Assoc; 2022 Aug; 121(8):1397-1405. PubMed ID: 34674904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
    Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
    Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea.
    Kang MG; Sohn KH; Kang DY; Park HK; Yang MS; Lee JY; Kang HR
    Yonsei Med J; 2019 Feb; 60(2):208-215. PubMed ID: 30666843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
    Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
    Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients.
    Garg VK; Buttar HS; Bhat SA; Ainur N; Priya T; Kashyap D; Tuli HS
    Recent Adv Inflamm Allergy Drug Discov; 2023; 17(2):110-120. PubMed ID: 37605396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.
    Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MH; Williams KM; Tian YC; Juan KC; Jan Wu YJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI
    Ann Rheum Dis; 2015 Dec; 74(12):2157-64. PubMed ID: 25115449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
    Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Cutaneous Adverse Reactions: A Single-Center Retrospective Study of 173 Patients in China.
    Xu Z; Shen J; Yang Y; Yuan R; Xiang LF; Zhang C
    Ann Dermatol; 2019 Oct; 31(5):545-554. PubMed ID: 33911647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea.
    Kang DY; Yun J; Lee SY; Koh YI; Sim DW; Kim S; Nam YH; Park JW; Kim SH; Ye YM; Park HK; Kim MH; Jee YK; Jung JW; Yang MS; Kim SH; Lee JK; Kim CW; Hur GY; Kim MY; Park SJ; Kwon YE; Choi JH; Kim JH; Kim SH; La HO; Kang MG; Park CS; Lee SM; Jeong YY; Kim HK; Jin HJ; Jeong JW; Lee J; Lee YW; Lee SE; Kim MS; Kang HR;
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):929-936.e7. PubMed ID: 32961314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
    Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
    Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
    Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
    Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
    Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
    Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries.
    Medina-Cáliz I; Sanabria-Cabrera J; Villanueva-Paz M; Aukštikalnė L; Stephens C; Robles-Díaz M; Pinazo-Bandera JM; García-Cortes M; Conde I; Soriano G; Bessone F; Hernandez N; Nunes V; Paraná R; Lucena MI; Andrade RJ; Niu H; Alvarez-Alvarez I
    Arch Toxicol; 2024 Jan; 98(1):303-325. PubMed ID: 38051367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.
    AlJasser MI
    Dermatol Res Pract; 2023; 2023():8928198. PubMed ID: 37206671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach.
    Sanabria-Cabrera J; Medina-Cáliz I; Stankevičiūtė S; Rodríguez-Nicolás A; Almarza-Torres M; Lucena MI; Andrade RJ
    Curr Pharm Des; 2019; 25(36):3855-3871. PubMed ID: 31696806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases.
    Devarbhavi H; Raj S; Aradya VH; Rangegowda VT; Veeranna GP; Singh R; Reddy V; Patil M
    Hepatology; 2016 Mar; 63(3):993-9. PubMed ID: 26439084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
    Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
    Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.